 Home > Active Ingredient News > Antitumor Therapy > Eur Urol: Patient preference of the first-line chemotherapy drugs cabazitaxel and docetaxel in metastatic castration-resistant prostate cancer

Eur Urol: Patient preference of the first-line chemotherapy drugs cabazitaxel and docetaxel in metastatic castration-resistant prostate cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

cd 1 2

artemisinin cancer protocol

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Docetaxel is the first treatment that can improve the overall survival (OS) of male patients with metastatic castration-resistant prostate cancer (mCRPC)
.

Cabazitaxel is a second-generation taxane drug that can maintain activity in some tumors that are resistant to docetaxel and new hormone therapies

Taxane drugs docetaxel and cabazitaxel can prolong the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC), and cabazitaxel is only approved for use after docetaxel treatment
.

Recent data show that they have similar efficacy in first-line mCRPC treatment, but their safety status is different

They have similar efficacy in the first-line mCRPC treatment, but the safety status is different.

The preferences of patients with docetaxel and cabazitaxel were evaluated.

Researchers randomly received docetaxel (75 mg/m2, every 3 weeks × 4 cycles) for mCRPC patients who had not undergone chemotherapy at a ratio of 1:1, and then received cabazitaxel (25 mg/m2, every 3 weeks × 4).
Cycle) treatment, or use the reverse order of administration, and stratify according to the previous use of abiraterone or enzalutamide
.

The primary end point was the patient's preference, which was assessed through a dedicated questionnaire after the second yew drug was used

Reasons for patient preference, prostate-specific antigen response, radiological progression-free survival and overall survival

Common factors affecting patient preference

To sum up, in the non-chemotherapy male patients treated with two taxanes, a higher proportion of patients prefer cabazitaxel to docetaxel
.

Less fatigue and better quality of life are the two main reasons for patient preference

Among the non-chemotherapy male patients treated with two taxanes, a higher proportion of patients preferred cabazitaxel to docetaxel

Original source:

Giulia Baciarello, Remy Delva, Gwenaelle Gravis et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.